Neonatal Sepsis Expert Meeting

2-3 August, 2016
Geneva, Switzerland

A joint WHO-DNDi Global Antibiotic Research and Development Partnership (GARDP) event which was organized to review and evaluate an important NeoAMR proposal and to form a consensus on the way forward.

 

Expert Meeting Summary

Meeting Agenda Day 1

Date: Tuesday, August 2, 2016

Welcome remarks
Anthony Costello, WHO, Switzerland
Opening & objectives
Manica Balasegaram, GARDP, DNDi, Switzerland
Global clinical epidemiology on pSBI and MDR NNUs
Anna Seale, LSTHM, UK
Global burden of neonatal AMR: Overview, current treatment options, NeoAMR project introduction
Mike Sharland, St George’s University, UK
Global variations in molecular AMR
Herman Goossens, University of Antwerp, Belgium
MDR in neonates in Africa
Gary Reubenson, University of Witwatersrand, South Africa
MDR in neonates in India
Ramesh Agarwal, AIIMS, India
Landscape analysis of old drugs to treat MDR gram-negatives
Céline Pulcini, University of Lorraine, France & Samir Saha, Dhaka Shishu Hospital, Bangladesh
Neo AMR work packages
Mike Sharland, St George’s University, UK & Manica Balasegaram, GARDP, DNDi, Switzerland

 

 

Meeting Agenda Day 2

Date: Wednesday, August 3, 2016

Role of global infectious disease networks
Herman Goossens, University of Antwerp, Belgium
Global neonatal networks and regulatory aspects
Mark Turner, University of Liverpool, UK
Learning from ANISA – building and running large neonatal infections studies
Samir Saha, Dhaka Shishu Hospital, Bangladesh
Running global paediatric infection  trials – learning from experience
Carlo Giaquinto, PENTA – ID
Strategic AMR trial design
Sarah Walker, MRC

Policy and pharmaceutical approaches to facilitate conservation and sustainable access strategies

  • Key elements of stewardship from local to global
  • Distribution models: What R&D incentives or how can risk be reduced?

Manica Balasegaram, GARDP, DNDi, Switzerland

Neonatal sepsis guidnace / EMLc
Anthony Costello, WHO, Switzerland & Liz Tayler, WHO, Switzerland
Target Product Profiles
– Purpose / indication
– Characteristics
Jutta Heim, GARDP, DNDi, Switzerland
NeoAMR proposal discussion
Mike Sharland, St George’s University, UK
Conclusions & next steps
Manica Balasegaram, GARDP, DNDi, Switzerland

 

 

More information:

 

Find out more about the Global Antibiotic Research and Development Partnership (GARDP)